Evaluation of Different Stabilizers and Inactivating Compounds for the Enhancement of Vero Cell Rabies Vaccine Stability and Immunogenicity: In Vitro Study
2019
Olayan, Ebtesam(Chair Vaccines Research of Infectious Diseases, Faculty of Science) | El-Khadragy, Manal(Chair Vaccines Research of Infectious Diseases, Faculty of Science) | Mohamed, Aly Fahmy(Holding Company for Production of Sera, Vaccines and Drugs (VACSEA)) | Mohamed, Amany Khalil(Holding Company for Production of Sera, Vaccines and Drugs (VACSEA)) | Shebl, Rania Ibrahim(Department of Microbiology and Immunology, Faculty of Pharmacy) | Yehia, Hany M.(Department of Food Science and Nutrition, College of Food and Agricultural Sciences)
Inactivation of rabies virus is essential for rabies vaccine preparation where the inactivating compound that is currently recommended for rabies vaccine preparation is β-propiolactone (β-PL). This compound is considered better than phenol and formalin but it is expensive and potentially carcinogenic. Data revealed that Ascorbic acid (AA) with cupric ions could yield complete and irreversible inactivation of rabies virus without adversely affecting its antigenicity. Additionally, the results of testing the vaccine potency with the selected inactivating compounds were comparable (P<0.05), and ED50 was higher than the recommended World Health Organization (WHO) limits. The use of HemaGel (plasma substitute) for testing vaccine stabilization was compared with the currently used vaccine stabilizers (human albumin and lactose). HemaGel yielded better stability than the other tested stabilizers. Monitoring of cellular and humoral immune responses indicated that both the total IgG level against rabies vaccine and the IFN and IL5 levels obtained with the HemaGel-stabilized vaccines were higher than those obtained with human albumin- and lactose-stabilized vaccine candidates.
显示更多 [+] 显示较少 [-]